⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024

Supplementary Figure 9 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy

Sarah Porte Alexandra Audemard‐Verger Christian Wu Aurélie Durand Théo Level Léa Giraud Amélie Lombès Mathieu Germain Rémi Pierre Benjamin Saintpierre Mireille Lambert Cédric Auffray Carole Peyssonnaux François Goldwasser Sophie Vaulont Marie‐Clotilde Alves‐Guerra Renaud Dentin Bruno Lucas Bruno Martin

View at Publisher

Ask AI

Bookmark

Share

Abstract

Iron and anti-PD1 cancer immunotherapy combination increases serum concentrations of IFN-γ, TNF-α and IL-2 in LLC tumor transplanted mice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Porte et al. (2024) studied this question.

synapsesocial.com/papers/68e598d9b6db6435875331d3 https://doi.org/10.1158/2326-6066.26926323

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 9 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024
2Supplementary Figure 4 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024
3Supplementary Figure 4 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024
4Supplementary Figure 3 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024
5Supplementary Figure 3 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024

More related papers

Supplementary Figure 8 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024
Supplementary Figure 8 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024
Supplementary Figure 10 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy2024